MPA
NVO

Marvin & Palmer Associates’s Novo Nordisk NVO Stock Holding History

Marvin & Palmer Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-121,094
Closed -$9.8M – 34
2023
Q2 		$9.8M Buy
121,094
+95,250
+369% +$7.78M 4.42% 10
2023
Q1 		$2.06M Sell
25,844
-356
-1% -$25.2K 1.04% 22
2022
Q4 		$1.77M Buy
+26,200
New +$1.54M 0.93% 23

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marvin & Palmer Associates's NVO Position: Q3 2023 in Review

Marvin & Palmer Associates sold out of Novo Nordisk (NVO) in Q3 2023, closing a stake of 121,094 shares — an estimated $9.8M sold.

Marvin & Palmer Associates first reported a position in NVO in Q4 2022 and held it in 3 quarters. The position peaked at $9.8M in Q2 2023. 1,308 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Marvin & Palmer Associates reported no remaining Novo Nordisk position as of Q3 2023 after selling out during the quarter.
  • Marvin & Palmer Associates sold 121,094 Novo Nordisk shares in Q3 2023, an estimated $9.8M.
  • Marvin & Palmer Associates first reported a position in Novo Nordisk in Q4 2022 and held it in 3 quarters.
  • Marvin & Palmer Associates's Novo Nordisk position peaked at $9.8M in Q2 2023.
  • 1,308 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Marvin & Palmer Associates's 13F filing for Q3 2023, filed 13 Nov 2023.